This guideline is intended to help manufacturers implementing modern quality systems and risk management approaches to meet the requirements of quality products to ensure their intended purpose and to protect the public health. The requirement in this guideline is established based on the mandate given to the Authority as stipulated in the Proclamation Number 661/2009 for the establishment of Food, Medicines and Healthcare Products in Ethiopia. GMP ensures that quality is built into the organization and processes involved in the manufacture of the products and all those operations should be carried out strictly according to cGMP. The guideline describes a comprehensive quality system model, which, if implemented, will allow manufacturers to support and sustain robust, modern quality systems that are consistent with cGMP regulations. The guideline consists of fifteen chapters and two annexes on manufacturing of sterile products and biological products. The inherent flexibility of the cGMP regulations should enable manufacturers to implement a quality system in a form that is appropriate for their specific operations. This guideline applies mainly to manufacturers of medicinal products (finished pharmaceuticals). However, the principles given under each chapter and the general requirements can be extended to the manufactures of food, medical devices, herbal medicines, cosmetics, etc. In future, the Authority will establish, where appropriate, specific cGMP requirements as supplements to the main guide to address matters related to certain product quality requirements. The guideline serves as a basic minimum requirement for both local pharmaceutical companies and foreign companies to be authorized for import products. It is also a reference and guidance tool to the Authority for GMP inspection and licensing of establishments. The requirement for establishment licensing is described in the guideline for establishment licensing. The guideline is a minimum requirement and as such does not restrict any new technological development and concept, which have been validated and installed in the manufacturing of products to improve the quality assurance system. The guideline shall be regularly reviewed and revised considering the needs and technological growth in the pharmaceutical sector.